Track market-moving stories before they get noisy

It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD - Free Report) . Shares have added about 0.5% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Acadia due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.

ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product SalesAcadia reported second-quarter 2026 earnings of 18 cents per share, which surpassed the Zacks Consensus Estimate of 6 cents. The company had reported earnings of 16 cents per share in the year-ago quarter.

Revenues of $308 million beat the Zacks Consensus Estimate of $294 million, reflecting a 16% year-over-year increase. Growth was supported by higher marketed product sales.

ACAD's Q2 Earnings in DetailAcadia’s revenues comprise net product sales from its two marketed drugs, Daybue and Nuplazid. Reported revenues increased from $264.6 million in the second quarter of 2025 to $308 million in the reported quarter.

The company’s quarterly performance benefited from continued demand for both products. Daybue growth was supported by the uptake of the recently launched Daybue STIX formulation, while Nuplazid benefited from volume growth and increased new-patient prescriptions.

Acadia's Nuplazid Sales Rise Year Over YearReported net product sales of Nuplazid were $183.2 million in the second quarter of 2026, up 9% from $168.5 million in the year-ago period. The drug is approved in the United States for treating hallucinations and delusions associated with Parkinson’s disease psychosis. Nuplazid sales beat the Zacks Consensus Estimate of $181.5 million.

Management stated that Nuplazid’s growth was primarily volume-driven. New-patient prescriptions increased 20% year over year and reached their highest quarterly level since the first quarter of 2018. Acadia also continued to expand engagement with priority health care providers through its enlarged field force.

ACAD's Daybue Sales Jump on STIX UptakeDaybue reported net product sales of $124.8 million, up 30% from $96.1 million in the second quarter of 2025. Daybue is approved in the United States for treating Rett syndrome in adult and pediatric patients two years of age and older. The reported figure beat the Zacks Consensus Estimate of $111.3 million.

Growth was driven largely by volume and strong uptake of Daybue STIX. Approximately 40% of U.S. Daybue patients were receiving STIX by the end of the quarter. The company also recorded a quarterly high in the number of patients returning to Daybue treatment.

Acadia stated that around 60% of total referrals during the quarter came from treatment-naive patients, while 40% represented returning patients. For STIX specifically, 55% of patients switched from the oral solution, while the remaining 45% were new or returning patients.

Acadia’s Operating Expenses Rise in Q2Research and development (R&D) expenses were $82 million in the second quarter of 2026, up 5% from $78 million in the year-ago period.

Selling, general and administrative (SG&A) expenses increased 20% year over year to $160 million from $134 million. The increase reflected investments in expanding the Nuplazid and Daybue field forces and higher marketing spending to support both brands.

Acadia had cash, cash equivalents and investment securities worth $956 million as of June 30, 2026, compared with $851 million as of March 31, 2026.

Acadia Raises Its 2026 Revenue OutlookFollowing the strong quarterly performance, Acadia raised its total revenue guidance for 2026 to a range of $1.24 billion to $1.30 billion. The previous guidance range was $1.22 billion to $1.28 billion.

The company increased its Daybue global net product sales forecast to $480-$510 million from the prior range of $460-$490 million. The revised outlook reflects strong U.S. demand, uptake of STIX and expected contributions from international markets.

Nuplazid net product sales guidance was maintained at $760-$790 million. Management expects the expanded field force to have a greater impact on Nuplazid’s performance later in the year as sales representatives deepen engagement with targeted physicians.

Acadia now expects R&D expense in the range of $355-$380 million, down from the previous range of $385-$410 million. SG&A expenses continue to be expected between $660 million and $700 million.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in estimates review.

The consensus estimate has shifted 59.62% due to these changes.

VGM ScoresAt this time, Acadia has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Acadia has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry PlayerAcadia belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Incyte (INCY - Free Report) , has gained 7.5% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.

Incyte reported revenues of $1.67 billion in the last reported quarter, representing a year-over-year change of +37.7%. EPS of $3.09 for the same period compares with $1.57 a year ago.

For the current quarter, Incyte is expected to post a loss of $3.31 per share, indicating a change of -246.5% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

Incyte has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of A.

Key Takeaways Acadia gained EU approval for Daybu, the first and only approved Rett syndrome treatment in the EU.Daybu is approved for neurobehavioral symptoms of Rett syndrome in adults and children aged five and older.The LAVENDER study showed meaningful improvements in Rett syndrome behavior and global impression. Acadia Pharmaceuticals (ACAD - Free Report) announced that the European Commission (EC) has granted marketing authorization for Daybu (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. The nod marks a major regulatory milestone for the therapy as it is now the first and only treatment approved for this indication in the EU.

The EU approval enables Acadia to expand Daybu’s commercial footprint across all 27 EU member states, as well as Iceland, Liechtenstein and Norway, strengthening the long-term growth potential of its rare disease franchise. As a next step, Acadia will now begin pricing and reimbursement negotiations with relevant national authorities to potentially bring Daybu to patients across the EU.

The EC approval was expected as the advisory committee to the European Medicines Agency adopted a positive opinion in June 2026 recommending the approval of Daybu for Rett Syndrome. It is a rare, neurodevelopmental disorder marked by developmental regression, severe motor impairment and lifelong care needs. The FDA approved trofinetide as the first and only treatment for Rett syndrome in adults and pediatric patients aged two years and older in 2023. The drug is marketed under the brand name Daybue in the United States. Daybue is also marketed (and available) in Canada and Israel for the same indication.

The EC approval is primarily supported by data from the pivotal phase III LAVENDER study, which demonstrated statistically significant and clinically meaningful improvements in key measures of Rett syndrome. The study met its co-primary endpoints, showing benefits on the Rett Syndrome Behavior Questionnaire and the Clinical Global Impression-Improvement scale, indicating that Daybu can improve some of the core neurobehavioral manifestations of the disease that substantially affect patients' daily functioning and caregiver burden.

Year to date, Acadia shares have gained 10.5% compared with the industry’s 11.1% growth.

Image Source: Zacks Investment Research

ACAD's Marketed Drugs Expected to Aid GrowthAcadia’s long-term growth is anchored by its two marketed products, Nuplazid and Daybue. The company continues to target approximately $1.7 billion in combined annual net sales by 2028, including roughly $1 billion for Nuplazid and $700 million for Daybue.

Nuplazid is the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis in the United States. The drug enjoys patent protection in the United States until 2038, giving it a long runway for revenue generation by protecting against generic erosion. In the first half of 2026, Nuplazid generated $350.1 million in net product sales, up 7% from the year-ago period. The increase was primarily driven by higher unit sales, highlighting continued underlying demand for the drug.

Since its launch in 2023, Daybue has witnessed encouraging sales uptake. The therapy generated $226 million in net product sales in the first half of 2026, up 25% year over year, with the increase primarily reflecting higher unit sales. The EU approval of the drug is expected to further boost sales in the upcoming quarters.

Meanwhile, Daybue STIX, a dye- and preservative-free powder formulation of trofinetide, was broadly launched in the United States in the second quarter of 2026. The formulation provides patients and caregivers greater flexibility while maintaining the same efficacy and safety profile as the original oral solution. Its strong uptake contributed to Daybue’s 30% year-over-year sales growth in the second quarter.

Overall, Acadia’s commercial portfolio remains on a solid growth trajectory. Following second-quarter results, the company raised its 2026 Daybue sales projection to $480-$510 million from the previous guided range of $460-$490 million while maintaining Nuplazid sales guidance of $760-$790 million.

ACAD's Zacks Rank & Stocks to ConsiderAcadia currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Amneal Pharmaceuticals (AMRX - Free Report) , Repligen (RGEN - Free Report) and AC Immune (ACIU - Free Report) . AMRX and RGEN currently sport a Zacks Rank #1 (Strong Buy) each, while ACIU carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, earnings estimates for Amneal Pharmaceuticals have increased from $1.00 to $1.02 for 2026. Over the same period, earnings estimates increased from $1.12 to $1.21 for 2027. AMRX shares have risen 42.1% year to date.

Amneal Pharmaceuticals beat earnings in each of the trailing four quarters, delivering an average surprise of 32.82%.

Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.61. RGEN shares have gained 10.6% year to date.

Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.

Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have lost 7.7% year to date.

AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the

Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large MovesACADIA Pharmaceuticals NASDAQ: ACAD outlined commercial expansion plans for its marketed therapies, DAYBUE and NUPLAZID, while highlighting upcoming clinical data for remlifanserin in Alzheimer’s disease psychosis during a discussion hosted by Canaccord Genuity.

Thomas Garner, Acadia’s chief commercial officer, said the company’s commercial strategy has centered on disease education, targeted outreach to healthcare providers and focused execution in both Parkinson’s disease psychosis and Rett syndrome.

Get ACADIA Pharmaceuticals alerts:

NUPLAZID Growth Strategy Garner said NUPLAZID, Acadia’s treatment for Parkinson’s disease psychosis, has continued to gain traction. New-to-brand prescriptions rose 20% year over year in the most recent quarter, he said.

The company has focused on raising awareness that hallucinations and delusions can occur during the course of Parkinson’s disease, while also educating healthcare providers about treatment options. Garner said Acadia estimates that about 1 million people in the U.S. are living with Parkinson’s disease and that roughly half may experience hallucinations and delusions during their disease course.

Acadia’s “More to Parkinson’s” awareness campaign, involving actor Ryan Reynolds, has contributed to a threefold increase in awareness of Parkinson’s disease psychosis among people living with Parkinson’s disease over the past two to three years, according to Garner.

To expand NUPLAZID’s reach, Acadia increased its sales force by roughly 40% earlier this year. The expansion increased the number of healthcare providers targeted by the company from approximately 5,000 to 6,000 to roughly 10,000 to 10,500, Garner said.

Garner said new treatments entering the broader Parkinson’s disease market could help improve disease awareness and diagnosis, potentially supporting demand for therapies addressing psychosis.

DAYBUE Formulation and Persistence DAYBUE, Acadia’s treatment for Rett syndrome, launched in 2023 and is the first and only approved treatment for the condition, according to Garner. Acadia estimates that about 6,000 people in the U.S., primarily young girls, are living with Rett syndrome.

Long-term patient persistence remains a central commercial focus. Garner said 12-month persistence is above 50% to 55%, while approximately 50% of patients remain on treatment at 18 months. He added that 70% of current DAYBUE patients have been receiving therapy for more than 12 months.

The company recently introduced DAYBUE STIX, a powder formulation that can be mixed with a non-dairy liquid. Garner said the formulation removes certain excipients contained in the earlier oral-solution version and may help Acadia reach treatment-naive patients as well as patients who previously discontinued DAYBUE.

In the second quarter, 60% of DAYBUE business came from the oral solution and 40% came from STIX. In June alone, however, 60% of prescriptions were for STIX, suggesting the newer formulation could become the leading form of the franchise over time, Garner said. He noted that some patients may remain on the oral solution because of the complexity of Rett syndrome and caregiver preferences.

Acadia also sees an opportunity to reengage approximately 1,000 Rett syndrome patients who previously tried and later stopped DAYBUE.

European and Japanese Expansion Garner said Acadia recently received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for DAYBUE and is preparing for a European Commission decision. The company plans to launch first in Germany after an EC decision and to submit pricing and reimbursement dossiers in additional priority markets.

Acadia estimates there are between 8,000 and 12,000 people living with Rett syndrome in the European Union, compared with about 6,000 in the U.S. Garner said the European opportunity is larger in patient numbers, though pricing and access conditions will vary by country.

The company is also conducting a DAYBUE trial in Japan. Garner said Acadia is evaluating a partnership-based approach to bringing the treatment to Japanese patients.

Pipeline and Business Development Acadia expects Phase II data for remlifanserin in Alzheimer’s disease psychosis in the September-to-October timeframe. Garner described the indication as a large commercial opportunity, estimating that 30% of the 7 million to 7.5 million people currently living with Alzheimer’s disease in the U.S. may develop psychosis.

He said Acadia believes remlifanserin could be differentiated by a profile suited to elderly patients with complex medical needs, though he emphasized that the company must first see how the data develop.

Al Kildani, Acadia’s senior vice president of investor relations and corporate communications, said the company also has a Phase II trial of remlifanserin in Lewy body dementia underway and expects Phase II data for ACP-211 in major depressive disorder in the latter part of next year.

Garner said Acadia has close to $1 billion in cash and is evaluating business-development opportunities ranging from near-term commercial assets to additions that could strengthen its mid-stage pipeline. He said the company is not required to pursue a transaction and intends to be selective about potential deals.

About ACADIA Pharmaceuticals (NASDAQ:ACAD)ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA's research centers concentrate on conditions with significant unmet medical needs, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company's flagship product, NUPLAZID® (pimavanserin), received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in ACADIA Pharmaceuticals Right Now?Before you consider ACADIA Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ACADIA Pharmaceuticals wasn't on the list.

While ACADIA Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Acadia Pharmaceuticals (ACAD - Free Report) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.

Analysts' growing optimism on the earnings prospects of this drugmaker is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- has this insight at its core.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

Consensus earnings estimates for the next quarter and full year have moved considerably higher for Acadia Pharmaceuticals, as there has been strong agreement among the covering analysts in raising estimates.

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate RevisionsThe company is expected to earn $0.15 per share for the current quarter, which represents a year-over-year change of -42.3%.

Over the last 30 days, the Zacks Consensus Estimate for Acadia has increased 18.02% because four estimates have moved higher compared to no negative revisions.

Current-Year Estimate RevisionsThe company is expected to earn $0.40 per share for the full year, which represents a change of -52.4% from the prior-year number.

In terms of estimate revisions, the trend for the current year also appears quite encouraging for Acadia. Over the past month, three estimates have moved higher compared to no negative revisions, helping the consensus estimate increase 6.57%.

Favorable Zacks RankOur research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom LineAcadia shares have added 10.8% over the past four weeks, suggesting that investors are betting on its impressive estimate revisions. So, you may consider adding it to your portfolio right away to benefit from its earnings growth prospects.

Key Takeaways Acadia reported Q2 EPS of 18 cents and revenues of $308M, both above consensus estimates. ACAD posted 16% total revenue growth as Daybue sales rose 30% and Nuplazid sales increased 9%.Acadia raised 2026 revenue guidance to $1.24-$1.30B after strong Q2 product sales. Acadia Pharmaceuticals (ACAD - Free Report) reported second-quarter 2026 earnings of 18 cents per share, which surpassed the Zacks Consensus Estimate of 6 cents. The company had reported earnings of 16 cents per share in the year-ago quarter.

Revenues of $308 million beat the Zacks Consensus Estimate of $294 million, reflecting a 16% year-over-year increase. Growth was supported by higher marketed product sales.

ACAD's Q2 Earnings in DetailAcadia’s revenues comprise net product sales from its two marketed drugs, Daybue (trofinetide) and Nuplazid (pimavanserin). Reported revenues increased from $264.6 million in the second quarter of 2025 to $308 million in the reported quarter.

The company’s quarterly performance benefited from continued demand for both products. Daybue growth was supported by the uptake of the recently launched Daybue STIX formulation, while Nuplazid benefited from volume growth and increased new-patient prescriptions.

Acadia's Nuplazid Sales Rise Year Over YearReported net product sales of Nuplazid were $183.2 million in the second quarter of 2026, up 9% from $168.5 million in the year-ago period. The drug is approved in the United States for treating hallucinations and delusions associated with Parkinson’s disease psychosis. Nuplazid sales beat the Zacks Consensus Estimate of $181.5 million.

Management stated that Nuplazid’s growth was primarily volume-driven. New-patient prescriptions increased 20% year over year and reached their highest quarterly level since the first quarter of 2018. Acadia also continued to expand engagement with priority health care providers through its enlarged field force.

ACAD's Daybue Sales Jump on STIX UptakeDaybue reported net product sales of $124.8 million, up 30% from $96.1 million in the second quarter of 2025. Daybue is approved in the United States for treating Rett syndrome in adult and pediatric patients two years of age and older. The reported figure beat the Zacks Consensus Estimate of $111.3 million.

Growth was driven largely by volume and strong uptake of Daybue STIX, a powder formulation for oral solution. Approximately 40% of U.S. Daybue patients were receiving STIX by the end of the quarter. The company also recorded a quarterly high in the number of patients returning to Daybue treatment.

Acadia stated that around 60% of total referrals during the quarter came from treatment-naive patients, while 40% represented returning patients. For STIX specifically, 55% of patients switched from the oral solution, while the remaining 45% were new or returning patients.

Year to date, Acadia shares have gained 1.7% compared with the industry’s 2.6% growth.

Image Source: Zacks Investment Research

Acadia’s Operating Expenses Rise in Q2Research and development (R&D) expenses were $82 million in the second quarter of 2026, up 5% from $78 million in the year-ago period.

Selling, general and administrative (SG&A) expenses increased 20% year over year to $160 million from $134 million. The increase reflected investments in expanding the Nuplazid and Daybue field forces and higher marketing spending to support both brands.

Acadia had cash, cash equivalents and investment securities worth $956 million as of June 30, 2026, compared with $851 million as of March 31, 2026.

Acadia Raises Its 2026 Revenue OutlookFollowing the strong quarterly performance, Acadia raised its total revenue guidance for 2026 to a range of $1.24 billion to $1.30 billion. The previous guidance range was $1.22 billion to $1.28 billion.

The company increased its Daybue global net product sales forecast to $480-$510 million from the prior range of $460-$490 million. The revised outlook reflects strong U.S. demand, uptake of STIX and expected contributions from international markets.

Nuplazid net product sales guidance was maintained at $760-$790 million. Management expects the expanded field force to have a greater impact on Nuplazid’s performance later in the year as sales representatives deepen engagement with targeted physicians.

Acadia now expects R&D expense in the range of $355-$380 million, down from the previous range of $385-$410 million. SG&A expenses continue to be expected between $660 million and $700 million.

ACAD Advances Its Neurology PipelineAcadia completed enrollment in the phase II portion of the RADIANT program evaluating remlifanserin in Alzheimer’s disease psychosis (ADP). The study enrolled 363 patients, and top-line results are expected between September and October 2026.

The company has also started screening and enrollment in two phase III studies of remlifanserin in ADP. The candidate received Fast Track designation from the FDA for treating hallucinations and delusions associated with ADP.

A separate phase II study of remlifanserin is underway in Lewy body dementia psychosis. Acadia is also evaluating ACP-211 in a phase II study for major depressive disorder, while ACP-711 and ACP-271 are progressing through phase I development.

Acadia also received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use recommending authorization of Daybu for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If approved, Daybu would become the first authorized treatment for Rett syndrome in the EU. A final European Commission decision is expected later in the third quarter of 2026.

ACAD's Zacks Rank & Stocks to ConsiderAcadia currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Harmony Biosciences (HRMY - Free Report) , Repligen (RGEN - Free Report)  and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Harmony Biosciences’ 2026 earnings per share have risen from $3.20 to $3.33, while estimates for 2027 have increased from $3.64 to $3.87 during the same time. HRMY shares have gained 3.5% year to date.

Harmony Biosciences’ earnings missed estimates in three of the trailing four quarters and beat on the remaining occasion, delivering an average negative surprise of 13.97%.

Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have declined 8.6% year to date.

Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.

Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 156.2% year to date.

Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.

Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large MovesACADIA Pharmaceuticals NASDAQ: ACAD reported second-quarter 2026 revenue of $308 million, representing 17% year-over-year growth on an adjusted basis, as sales of its Rett syndrome therapy DAYBUE and Parkinson’s disease psychosis treatment NUPLAZID increased.

Chief Executive Officer Catherine Owen Adams said the quarter reflected strong commercial execution across both brands, while the company also advanced its pipeline, led by remlifanserin for Alzheimer’s disease psychosis.

Get ACADIA Pharmaceuticals alerts:

DAYBUE generated $125 million in second-quarter net sales, up 30% from a year earlier. NUPLAZID produced $183 million in net sales, up 10% year over year on an adjusted basis. ACADIA raised its full-year DAYBUE sales outlook while maintaining its NUPLAZID guidance.

DAYBUE STIX Drives Growth DAYBUE growth was driven primarily by volume, including adoption of DAYBUE STIX, the company’s powder-for-oral-solution formulation. Chief Commercial Officer Thomas Garner said approximately 40% of U.S. DAYBUE patients were receiving STIX by the end of the quarter.

Garner said the expanded launch beyond Centers of Excellence helped engage new patients and bring previously discontinued patients back to therapy. The number of patients returning to DAYBUE reached a record during the quarter, he said.

Of referrals during the quarter across DAYBUE formulations, about 60% came from treatment-naive patients and 40% from returning patients, according to Garner. Looking specifically at STIX users, he said 55% of existing patients were switching from the oral solution, while 45% were new or returning patients. Among that latter group, approximately 60% were new patients and 40% were returning patients.

ACADIA raised its 2026 DAYBUE net sales guidance to $480 million to $510 million, from a prior range of $460 million to $490 million. The outlook includes expected initial European commercial sales in the fourth quarter.

The company recently received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, for trofinetide, the active ingredient in DAYBUE, following a re-examination process. ACADIA expects a European Commission decision later in the third quarter and plans to launch in Germany in early fourth quarter, followed by other European markets as reimbursement approvals are obtained.

Garner said ACADIA expects less than 50% of its stated $700 million DAYBUE sales target for 2028 to come from Europe. The company said it currently expects roughly 15% of 2028 DAYBUE sales to come from outside the U.S., subject to reimbursement decisions and pricing negotiations.

NUPLAZID Prescription Momentum Continues NUPLAZID’s adjusted 10% sales growth was primarily volume-driven, with volume up 8% year over year. Garner said new patient prescriptions increased 20% from a year earlier and reached their highest quarterly level since the first quarter of 2018.

The company has expanded its commercial field force and said it is beginning to see benefits from that investment, which it had expected to take six to nine months to ramp. Since February, the expanded team has reached more than 12,000 priority healthcare providers, according to Garner.

ACADIA also cited direct-to-consumer awareness efforts, including its “Mind Your Mind” and “More to Parkinson’s” campaigns during Parkinson’s Awareness Month in April. Garner said the campaigns produced record audience reach and increased branded and unbranded patient conversion sequentially.

NUPLAZID refill and restart rates were in line with the company’s expectations, Garner said in response to an analyst question. ACADIA maintained its 2026 NUPLAZID net sales guidance of $760 million to $790 million and expects stronger year-over-year growth in the fourth quarter than in the third quarter as the field-force expansion gains traction.

Remlifanserin Data Expected This Fall ACADIA completed enrollment in the phase II portion of its RADIANT study of remlifanserin in Alzheimer’s disease psychosis. Executive Vice President and Head of Research and Development Elizabeth Thompson said top-line results are now expected between September and October.

The Food and Drug Administration granted Fast Track designation to remlifanserin for Alzheimer’s disease psychosis. ACADIA has also begun screening and enrollment in its phase III studies under an operationally seamless phase II/phase III program design.

Thompson said the phase II portion enrolled 363 patients and is powered at 80% to detect a 0.4 effect size on the Scale for the Assessment of Positive Symptoms Hallucinations and Delusions, or SAPS H&D. The phase III studies are currently enrolling placebo, 30-milligram, and 60-milligram dosing arms, with the company retaining the ability to modify the phase III program after reviewing phase II data.

ACADIA estimates remlifanserin could have $4 billion in peak sales potential across Alzheimer’s disease psychosis and Lewy body dementia psychosis. Management said it currently views that opportunity as roughly 60% attributable to Alzheimer’s disease psychosis and 40% to Lewy body dementia psychosis, though the split will depend on clinical data and the competitive environment.

Elsewhere in the pipeline, ACADIA expects phase III trofinetide data from Japan between September and November and plans a potential regulatory submission in Japan in 2027. The Japanese trial includes roughly 20 patients and is intended primarily to provide experience in Japanese patients, with ACADIA’s prior LAVENDER data expected to serve as the primary basis of a future filing package.

Expenses, Cash and Updated Outlook Research and development expense was $82 million in the quarter, compared with $78 million a year earlier. Selling, general and administrative expense rose to $160 million from $134 million, reflecting investments in the DAYBUE and NUPLAZID field forces and marketing support for both brands.

Chief Financial Officer Mark Schneyer said ACADIA ended the quarter with $956 million in cash. The company now expects 2026 total revenue of $1.24 billion to $1.3 billion.

ACADIA lowered its expected 2026 R&D expense range to $355 million to $380 million, from prior guidance of $385 million to $410 million. Schneyer said the reduction reflected a business-development milestone shifting to 2027 and selected portfolio prioritization decisions. Other fiscal-year guidance ranges were unchanged.

About ACADIA Pharmaceuticals (NASDAQ:ACAD)ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA's research centers concentrate on conditions with significant unmet medical needs, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company's flagship product, NUPLAZID® (pimavanserin), received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in ACADIA Pharmaceuticals Right Now?Before you consider ACADIA Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ACADIA Pharmaceuticals wasn't on the list.

While ACADIA Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

- Second quarter DAYBUE® GAAP net sales of $125 million, up 30% year-over-year driven by strong uptake of DAYBUE STIX

- Second quarter NUPLAZID® GAAP net sales of $183 million, up 10% year-over-year on a non-GAAP adjusted basis

- Increased full year 2026 total revenue guidance to $1.24 to $1.30 billion, reflecting higher DAYBUE guidance of $480 to $510 million and reaffirmed NUPLAZID guidance of $760 to $790 million

- Topline results from the Phase 2 remlifanserin study in Alzheimer’s disease psychosis anticipated September to October 2026

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2026.

“Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growth of 17% year-over-year on an adjusted basis,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “For DAYBUE, continued patient demand and robust uptake of STIX drove another quarter of strong performance. For NUPLAZID, we continued to see strong momentum, especially in new-to-brand prescriptions as our recently expanded sales force gained traction in the field. We remain confident that both franchises are on track to achieve our long-term ambition of approximately $1.7 billion in annual net sales in 2028. Looking ahead, we are excited about the anticipated topline results from our Phase 2 program evaluating remlifanserin in Alzheimer's disease psychosis in the September to October timeframe, which we believe represents a potentially transformational opportunity for Acadia.”

Company Updates

Completed enrollment in the Phase 2 portion of the RADIANT program evaluating remlifanserin in Alzheimer's disease psychosis and initiated Phase 3 screening and enrollment; topline Phase 2 results are expected in September to October 2026. Received FDA Fast Track designation for remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis, recognizing its potential to address a significant unmet medical need. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If approved by the European Commission, DAYBU would become the first authorized treatment for Rett syndrome in the European Union. Financial Results

Revenues

GAAP total revenues, comprised of net product sales from NUPLAZID and DAYBUE, were $308 million for the second quarter of 2026, up 16% as compared to GAAP total revenues of $265 million in the second quarter of 2025, and up 17% as compared to non-GAAP adjusted total revenues of $262 million in the second quarter of 2025.

GAAP net product sales of NUPLAZID were $183 million for the second quarter of 2026, up 9% compared to GAAP net product sales of $168 million for the second quarter of 2025, and up 10% as compared to non-GAAP adjusted net product sales of $166 million for the second quarter of 2025.

Net product sales of DAYBUE were $125 million for the second quarter of 2026, an increase of 30% as compared to $96 million for the second quarter of 2025.

A reconciliation of NUPLAZID non-GAAP adjusted net product sales and non-GAAP adjusted total revenues is provided in Table 1. A description of these adjustments is included under ‘Non-GAAP Financial Measures.’

Research and Development

Research and development expenses for the second quarter of 2026 were $82 million, compared to $78 million for the same period of 2025.

Selling, General and Administrative

Selling, general and administrative expenses for the second quarter of 2026 were $160 million, compared to $134 million for the same period of 2025.

Net Income

For the second quarter of 2026, Acadia reported net income of $32 million, or $0.18 per diluted share, compared to a net income of $27 million, or $0.16 per diluted share, for the same period in 2025.

Cash and Investments

At June 30, 2026, Acadia’s cash, cash equivalents, and investment securities totaled $956 million, compared to $820 million at December 31, 2025.

Full Year 2026 Financial Guidance (GAAP):

Acadia is updating its 2026 guidance:

Total revenues revised to a range of $1.24 to $1.30 billion, up from the previous range of $1.22 to $1.28 billion. NUPLAZID net product sales in the range of $760 to $790 million. DAYBUE (including all forms of trofinetide) global net product sales in the range of $480 to $510 million, up from the previous range of $460 to $490 million. R&D expense in the range of $355 to $380 million, down from the previous range of $385 to $410 million. SG&A expense in the range of $660 to $700 million. Conference Call and Webcast Information

Acadia will host a conference call to discuss the second quarter 2026 results today, Tuesday, August 4, 2026 at 1:30 p.m. PT/4:30 p.m. ET. The conference call may be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.

About NUPLAZID® (pimavanserin)

Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors. Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis by the U.S. Food and Drug Administration in April 2016 under the trade name NUPLAZID.

About DAYBUE® (trofinetide)

Trofinetide is a synthetic version of a naturally occurring molecule known as the tripeptide glycine-proline-glutamate (GPE). The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown. Trofinetide was approved for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older by the U.S. Food and Drug Administration in March 2023 under the trade name DAYBUE or DAYBUE STIX.

About Acadia Pharmaceuticals

Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.

Non-GAAP Financial Measures

This press release contains the following financial measures that do not comply with U.S. generally accepted accounting principles (GAAP): non-GAAP adjusted net product sales for NUPLAZID for the second quarter of 2025 and non-GAAP adjusted total revenues for the second quarter of 2025. In preparing these non-GAAP financial results, the Company includes adjustments made to reflect the impact of a change in estimate related to NUPLAZID IRA rebate accruals. Please refer to our press release dated February 25, 2026, for additional details. These non-GAAP financial measures complement GAAP results and are used by management to analyze financial performance and evaluate period-to-period changes. Management believes these non-GAAP financial measures are useful to investors and other users of the Company’s financial statements to facilitate period-to-period comparability. These non-GAAP financial measures are not meant to be considered as a substitute for comparable GAAP measures; should be read in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are unlikely to be comparable with non-GAAP disclosures released by other companies.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential,” “guidance,” “continue” and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) our business strategy, objectives and opportunities, including support for and innovations in our pipeline assets and business development opportunities, sales growth for DAYBUE and uptake in DAYBUE STIX, and potential for enhanced shareholder value; (ii) the momentum and expectations for NUPLAZID with the expanded sales force, (iii) the FDA’s potential review of a new drug application for remlifanserin as a treatment for Alzheimer’s disease psychosis, (iv) the receipt and timing of the topline results of the RADIANT Phase 2 study, the transformational opportunity of those results, and the enrollment of the Phase 3 portion of the RADIANT development program, (v) potential approval of DAYBU (trofinetide) in the European Union, (vi) plans for, including timing, development and progress of commercialization or regulatory timelines for our products and our product candidates; (vii) benefits to be derived from and efficacy of our products, including the potential advantages of our products; and (viii) our estimates regarding our future financial performance, profitability, capital requirements or expenses, including our full year 2026 financial guidance and anticipated net product sales by the end of 2028. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our dependency on the continued successful commercialization of our products and our ability to maintain or increase sales of our products; the success of our plans to continue commercial growth; the costs of our commercialization plans and development programs, and the financial impact or revenues from any commercialization we undertake; our ability to obtain necessary regulatory approvals for our product candidates and, if and when approved, market acceptance of our products; the risks associated with clinical trials and their outcomes, including risks of unsuccessful enrollment and negative or inconsistent results; our dependence on third-party collaborators, clinical research organizations, manufacturers, suppliers and distributors; the impact of competitive products and therapies; our ability to generate or obtain the necessary capital to fund our operations; our ability to grow, equip and train our specialized sales forces; our ability to manage the growth and complexity of our organization; our ability to maintain, protect and enhance our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-K for the year ended December 31, 2025 as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.

ACADIA PHARMACEUTICALS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

(Unaudited)

  Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Revenues

Product sales, net

$

307,959

$

264,566

$

576,021

$

508,882

Total revenues

307,959

264,566

576,021

508,882

Operating expenses

Cost of product sales (1)(2)

28,316

20,734

53,107

41,126

Research and development (2)

81,555

77,951

158,423

156,216

Selling, general and administrative (2)

160,252

133,507

331,271

259,877

Total operating expenses

270,123

232,192

542,801

457,219

(Loss) income from operations

37,836

32,374

33,220

51,663

Interest income, net

7,990

7,243

16,045

15,144

Other income

647

594

1,189

1,183

Income before income taxes

46,473

40,211

50,454

67,990

Income tax expense

14,973

13,545

15,317

22,337

Net income

$

31,500

$

26,666

$

35,137

$

45,653

Earnings per share:

Basic

$

0.18

$

0.16

$

0.21

$

0.27

Diluted

$

0.18

$

0.16

$

0.20

$

0.27

Weighted average common shares outstanding:

Basic

171,603

167,827

171,063

167,321

Diluted

172,851

168,681

172,890

168,219

(1) Includes license fees and royalties

(2) Includes the following stock-based compensation expense

Cost of product sales

$

510

$

18

$

838

$

352

Research and development

$

4,746

$

4,477

$

8,888

$

7,910

Selling, general and administrative

$

11,684

$

9,845

$

21,912

$

17,458

ACADIA PHARMACEUTICALS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(Unaudited)

  June 30,
2026

December 31,
2025

(unaudited)

Assets

Cash, cash equivalents and investment securities

$

956,474

$

819,686

Accounts receivable, net

150,642

121,457

Interest and other receivables

15,688

26,774

Inventory

32,372

34,670

Prepaid expenses and other current assets

69,369

59,526

Total current assets

1,224,545

1,062,113

Property and equipment, net

17,107

7,511

Operating lease right-of-use assets

69,424

47,354

Intangible assets, net

103,448

108,893

Restricted cash

7,846

7,845

Long-term inventory

76,301

76,704

Deferred tax assets

240,679

249,879

Other assets

3,550

3,896

Total assets

$

1,742,900

$

1,564,195

Liabilities and stockholders’ equity

Accounts payable

$

44,566

$

10,903

Accrued liabilities

316,870

266,211

Total current liabilities

361,436

277,114

Operating lease liabilities

59,547

40,554

Other long-term liabilities

15,308

19,137

Total liabilities

436,291

336,805

Total stockholders’ equity

1,306,609

1,227,390

Total liabilities and stockholders’ equity

$

1,742,900

$

1,564,195

Table 1. ACADIA PHARMACEUTICALS INC.

NON-GAAP RECONCILIATION

(in millions)

(Unaudited)

  2Q25

2Q26

GAAP NUPLAZID Net Sales

$

168.5

$

183.2

Allocation of 2025 Amount

$

(2.4

)

$

—

Non-GAAP Adjusted NUPLAZID Net Sales

$

166.1

$

183.2

DAYBUE products Net Sales

$

96.1

$

124.8

Non-GAAP Adjusted Total Revenues

$

262.2

$

308.0

More News From Acadia Pharmaceuticals Inc.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 1:30 p.m. Eastern Time. Live webcasts will be accessible on the company's website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation. About Acadia Pharmaceuticals Acadia is commit.

3.49K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Posted by Defense World Staff on Jul 22nd, 2026

Bessemer Group Inc. lifted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 21,126.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 150,498 shares of the biopharmaceutical company’s stock after buying an additional 149,789 shares during the period. Bessemer Group Inc. owned approximately 0.09% of ACADIA Pharmaceuticals worth $3,350,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC boosted its stake in ACADIA Pharmaceuticals by 44.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 954,855 shares of the biopharmaceutical company’s stock valued at $21,312,000 after acquiring an additional 296,042 shares in the last quarter. Illinois Municipal Retirement Fund grew its holdings in shares of ACADIA Pharmaceuticals by 12.7% during the first quarter. Illinois Municipal Retirement Fund now owns 71,183 shares of the biopharmaceutical company’s stock worth $1,585,000 after purchasing an additional 7,996 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its position in shares of ACADIA Pharmaceuticals by 30.6% during the first quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 12,923 shares of the biopharmaceutical company’s stock worth $288,000 after purchasing an additional 3,026 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of ACADIA Pharmaceuticals by 3.1% during the first quarter. Principal Financial Group Inc. now owns 768,224 shares of the biopharmaceutical company’s stock worth $17,101,000 after purchasing an additional 22,868 shares in the last quarter. Finally, Fifth Third Bancorp lifted its holdings in shares of ACADIA Pharmaceuticals by 5,053.5% in the 1st quarter. Fifth Third Bancorp now owns 31,694 shares of the biopharmaceutical company’s stock valued at $706,000 after purchasing an additional 31,079 shares during the last quarter. 96.71% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at ACADIA Pharmaceuticals In related news, insider James Kihara sold 5,401 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total transaction of $114,393.18. Following the completion of the sale, the insider directly owned 24,509 shares of the company’s stock, valued at $519,100.62. This trade represents a 18.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Mark C. Schneyer sold 3,506 shares of ACADIA Pharmaceuticals stock in a transaction on Monday, May 4th. The shares were sold at an average price of $21.79, for a total transaction of $76,395.74. Following the completion of the transaction, the executive vice president owned 66,145 shares in the company, valued at approximately $1,441,299.55. This trade represents a 5.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 10,239 shares of company stock valued at $219,813 in the last 90 days. Company insiders own 26.20% of the company’s stock.

ACADIA Pharmaceuticals Stock Up 1.4% NASDAQ ACAD opened at $25.43 on Wednesday. ACADIA Pharmaceuticals Inc. has a 52-week low of $19.69 and a 52-week high of $28.35. The business’s 50-day moving average price is $23.05 and its 200 day moving average price is $23.27. The firm has a market cap of $4.35 billion, a P/E ratio of 11.56, a P/E/G ratio of 18.07 and a beta of 0.80.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02). ACADIA Pharmaceuticals had a net margin of 34.30% and a return on equity of 9.61%. The company had revenue of $268.10 million for the quarter, compared to analysts’ expectations of $280.25 million. During the same period in the prior year, the company earned $0.11 earnings per share. The firm’s revenue was up 9.7% on a year-over-year basis. As a group, analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.37 earnings per share for the current year.

Wall Street Analyst Weigh In A number of brokerages recently issued reports on ACAD. Weiss Ratings cut ACADIA Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 1st. HC Wainwright lowered ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, June 30th. Royal Bank Of Canada boosted their price objective on ACADIA Pharmaceuticals from $29.00 to $36.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Citigroup increased their price objective on ACADIA Pharmaceuticals from $32.00 to $35.00 and gave the company a “buy” rating in a report on Monday, June 29th. Finally, BMO Capital Markets raised their target price on shares of ACADIA Pharmaceuticals from $34.00 to $36.00 and gave the stock an “outperform” rating in a research report on Tuesday. Thirteen analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.17.

Check Out Our Latest Research Report on ACAD

About ACADIA Pharmaceuticals (Free Report)

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.

See Also Five stocks we like better than ACADIA Pharmaceuticals Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINED.A. Davidson & CO. Has $1.84 Million Holdings in Welltower Inc. $WELL

NEXT HEADLINE »Bessemer Group Inc. Purchases 529,678 Shares of Adamas Trust, Inc. $ADAM

Posted by Defense World Staff on Jul 21st, 2026

Allspring Global Investments Holdings LLC lifted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 44.9% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 954,855 shares of the biopharmaceutical company’s stock after buying an additional 296,042 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.56% of ACADIA Pharmaceuticals worth $21,312,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ACAD. Illinois Municipal Retirement Fund grew its stake in ACADIA Pharmaceuticals by 12.7% during the first quarter. Illinois Municipal Retirement Fund now owns 71,183 shares of the biopharmaceutical company’s stock valued at $1,585,000 after acquiring an additional 7,996 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its holdings in shares of ACADIA Pharmaceuticals by 30.6% during the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 12,923 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 3,026 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of ACADIA Pharmaceuticals by 3.1% during the first quarter. Principal Financial Group Inc. now owns 768,224 shares of the biopharmaceutical company’s stock valued at $17,101,000 after purchasing an additional 22,868 shares in the last quarter. Fifth Third Bancorp grew its position in shares of ACADIA Pharmaceuticals by 5,053.5% during the first quarter. Fifth Third Bancorp now owns 31,694 shares of the biopharmaceutical company’s stock valued at $706,000 after purchasing an additional 31,079 shares in the last quarter. Finally, Hsbc Holdings PLC increased its holdings in shares of ACADIA Pharmaceuticals by 67.4% in the first quarter. Hsbc Holdings PLC now owns 44,008 shares of the biopharmaceutical company’s stock worth $977,000 after purchasing an additional 17,722 shares during the last quarter. Institutional investors own 96.71% of the company’s stock.

Wall Street Analysts Forecast Growth A number of equities research analysts recently commented on the company. Bank of America boosted their target price on ACADIA Pharmaceuticals from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $37.00 price target on shares of ACADIA Pharmaceuticals in a report on Monday, June 29th. Citigroup boosted their price objective on ACADIA Pharmaceuticals from $32.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Canaccord Genuity Group raised their price objective on ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Weiss Ratings cut ACADIA Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 1st. Twelve research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $32.94.

View Our Latest Research Report on ACAD

ACADIA Pharmaceuticals Stock Performance Shares of NASDAQ ACAD opened at $25.09 on Tuesday. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $19.69 and a fifty-two week high of $28.35. The company has a market cap of $4.30 billion, a price-to-earnings ratio of 11.40, a PEG ratio of 18.44 and a beta of 0.80. The business’s 50 day moving average price is $22.98 and its 200-day moving average price is $23.28.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The company had revenue of $268.10 million during the quarter, compared to the consensus estimate of $280.25 million. ACADIA Pharmaceuticals had a return on equity of 9.61% and a net margin of 34.30%.The company’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.11 earnings per share. Sell-side analysts predict that ACADIA Pharmaceuticals Inc. will post 0.37 earnings per share for the current year.

Insider Activity at ACADIA Pharmaceuticals In other news, insider James Kihara sold 5,401 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total transaction of $114,393.18. Following the transaction, the insider owned 24,509 shares of the company’s stock, valued at approximately $519,100.62. This represents a 18.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Mark C. Schneyer sold 3,506 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $21.79, for a total value of $76,395.74. Following the transaction, the executive vice president owned 66,145 shares in the company, valued at approximately $1,441,299.55. This represents a 5.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 10,239 shares of company stock valued at $219,813 in the last ninety days. Insiders own 26.20% of the company’s stock.

ACADIA Pharmaceuticals Profile (Free Report)

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.

Featured Stories Five stocks we like better than ACADIA Pharmaceuticals The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAllspring Global Investments Holdings LLC Has $21.26 Million Position in ITT Inc. $ITT

NEXT HEADLINE »Allspring Global Investments Holdings LLC Reduces Stock Position in Sempra Energy $SRE

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on August 4, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived for approximately 90 days. The conference ca.

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX) and Acadia Pharmaceuticals (ACAD). But which of these two companies is the best option for those looking for undervalued stocks?

Key Takeaways ACAD up 6.8% after the CHMP recommended Daybu for EU approval in Rett syndrome following re-examination.Daybu could become the first EU-approved treatment for Rett syndrome's neurobehavioral symptoms.Acadia's phase III LAVENDER data supported the positive opinion after an earlier CHMP refusal. Acadia Pharmaceuticals (ACAD - Free Report) shares climbed 6.8% on Friday after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion following a re-examination procedure, recommending the approval of Daybu (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. The recommendation marks a major regulatory turnaround for the therapy, which could become the first approved treatment for this indication in the EU.

The positive CHMP recommendation represents an important milestone for Acadia as it seeks to expand Daybu's commercial footprint. Rett syndrome is a rare neurodevelopmental disorder with no therapies currently approved in the EU specifically for its neurobehavioral symptoms, leaving patients with limited treatment options. An approval would allow Acadia to address a significant unmet medical need while strengthening the long-term growth prospects of its rare disease franchise.

The CHMP's favorable opinion was primarily supported by data from the pivotal phase III LAVENDER study, which demonstrated statistically significant and clinically meaningful improvements in key measures of Rett syndrome. The study met its co-primary endpoints, showing benefits on the Rett Syndrome Behavior Questionnaire and the Clinical Global Impression-Improvement scale, indicating that Daybu can improve some of the core neurobehavioral manifestations of the disease that substantially affect patients' daily functioning and caregiver burden.

Following the CHMP recommendation, the European Commission (EC) will review the agency's opinion before issuing a final regulatory decision, which is expected in the coming months. If approved, Daybu's centralized marketing authorization would be valid across all 27 EU member states as well as Iceland, Liechtenstein and Norway, significantly expanding access to the therapy across Europe.

The FDA approved trofinetide as the first and only treatment for Rett syndrome in adults and pediatric patients aged two years and older in 2023. The drug is marketed under the brand name Daybue in the United States. Daybue is also marketed (and available) in Canada and Israel for the same indication.

Year to date, Acadia shares have lost 5.2% against the industry’s 5.2% growth.

Image Source: Zacks Investment Research

Earlier CHMP Refusal Delayed EU Expansion of ACAD’s DaybuThe latest recommendation follows a significant regulatory setback earlier this year, when the CHMP formally adopted a negative opinion recommending against the approval of trofinetide for the treatment of Rett syndrome in patients aged two years and older in the EU. The decision came after the committee had previously notified Acadia of a negative trend vote on the marketing application in early February, prompting the company to seek a formal re-examination of the application.

Although the pivotal LAVENDER study had achieved its co-primary and key secondary endpoints, the CHMP had previously concluded that several aspects of the evidence package limited its ability to support approval. The committee viewed the treatment benefit observed after 12 weeks as modest, questioned whether the study adequately captured all core symptoms of Rett syndrome and expressed concerns that patient discontinuations may have affected the interpretation of longer-term outcomes.

Following the initial refusal, Acadia reviewed the CHMP's objections in detail and proceeded with the re-examination process, ultimately securing the positive recommendation now under consideration by the EC. The favorable outcome substantially improves the therapy's regulatory outlook in Europe and revives the company's efforts to bring Daybu to patients across the region.

ACAD's Marketed Drugs Expected to Aid GrowthAcadia’s long-term growth is supported by its lead product, Nuplazid and Daybue in the United States. The company expects to generate around $1.7 billion in combined net sales by 2028, including $1 billion for Nuplazid and $700 million for Daybue.

Nuplazid is the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis in the United States. The drug enjoys patent protection in the United States until 2038, which gives it a long runway for revenue generation by protecting against generic erosion. In the first quarter of 2026, Nuplazid recorded $167 million in sales, up 5% year over year, driven primarily by volume growth.

Since its launch in 2023, Daybue has witnessed encouraging sales uptake. In the first quarter of 2026, Daybue recorded $101 million in sales, up 20% year over year, driven by growth in the drug’s unit sales as Acadia shipped it to more unique patients. A potential EU approval could further boost sales.

In late 2025, the FDA approved Daybue Stix (trofinetide) for oral solution, a dye- and preservative-free powder formulation for the treatment of Rett syndrome in adults and pediatric patients aged two years and older. The new product expands the Daybue franchise, which remains the only FDA-approved treatment option for this indication.

Per Acadia, the full U.S. launch of Daybue STIX is underway, with nearly 30% of patients using STIX either new to treatment or resuming therapy after previously discontinuing the liquid formulation. The company will continue to offer both formulations in the United States, strengthening its positioning in the Rett syndrome treatment market.

ACAD's Zacks Rank & Stocks to ConsiderAcadia currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Liquidia Corporation (LQDA - Free Report) , Indivior Pharmaceuticals (INDV - Free Report) and Immunocore (IMCR - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Liquidia Corporation’s 2026 EPS have increased from $1.50 to $2.97. Over the same period, EPS estimates for 2027 have also increased from $2.91 to $4.81. LQDA shares have rallied 126.7% year to date.

Liquidia Corporation’searnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.

Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.34 to $4.05. Over the same period, EPS estimates for 2027 have risen to $4.27 from $3.56. INDV shares have gained 16.6% year to date.

Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.

The estimate for Immunocore’s 2026 EPS is currently pegged at 6 cents. In the past 60 days, the estimates for its 2027 EPS have increased from 24 cents to 87 cents. IMCR shares have lost 11% year to date.

Immunocore’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 46.66%.

HomeStock IdeasLong IdeasHealthcare 

SummaryAcadia Pharmaceuticals demonstrates steady commercial growth with Nuplazid and Daybue, supported by a recent positive CHMP opinion for Daybue in Europe.Remlifanserin's upcoming phase 2 readout in Alzheimer's disease psychosis is a high-risk, high-reward catalyst not priced into ACAD's current valuation.I maintain a bullish outlook on ACAD based on commercial products Nuplazid and Daybue, but above-average returns depend on pipeline or business development success.ACAD's valuation remains below the combined Nuplazid and Daybue value, with $851M cash and positive cash flows supporting future pipeline expansion.Looking for more investing ideas like this one? Get them exclusively at Growth Stock Forum. Learn More »Sitewide Sale 2026: Get 20% Off BeritK/iStock via Getty Images

It has been more than a year since I last wrote about Acadia Pharmaceuticals (ACAD). Since then, we saw the failure of ACP-101 in Prader-Willi syndrome, which I wrote was a realistic possibility

9.58K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This article reflects the author's opinion and should not be regarded as a buy or sell recommendation or investment advice in any way.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

This news comes during a mixed market day, with the health care sector gaining about 2.76%, while the broader S&P 500 remains flat.

• ACADIA Pharmaceuticals stock is charging ahead with explosive momentum. What’s fueling ACAD momentum?

ACAD Stock Jumps On CHMP Recommendation For DAYBU In EUThe CHMP has recommended granting marketing authorization for DAYBU (trofinetide), which, if approved by the European Commission, would be the first treatment for Rett syndrome symptoms in the EU.

This recommendation is based on positive results from the Phase 3 LAVENDER study, which showed significant improvements in core features of the condition.

In February, the CHMP voted negatively for trofinetide for Rett syndrome, following its recent CHMP oral explanation.

ACAD Technical Analysis: Momentum, Overbought Signals and ResistanceAcadia Pharmaceuticals is currently trading at $26.57, significantly above its 20-day simple moving average (SMA) of $22.02, indicating strong short-term momentum.

The stock is also 23.1% above its 20-day SMA, suggesting a bullish trend, although the relative strength index (RSI) is at 82.37, indicating that the stock is in overbought territory.

While the 50-day SMA is below the current price, the 50-day SMA has recently crossed below the 200-day SMA, marking a death cross in March, which could signal caution for longer-term investors.

The stock’s current price is also nearing key resistance at $28, which could be a pivotal point for future price action.

How ACAD Ranks On Value and MomentumBelow is the Benzinga Edge scorecard for Acadia Pharmaceuticals, highlighting its strengths and weaknesses compared to the broader market:

Value: 63.15 — The stock is reasonably valued relative to peers. Momentum: 29.67 — Stock is underperforming the broader market. The Verdict: Acadia Pharmaceuticals’ Benzinga Edge signal reveals a mixed profile, with a solid value ranking but weak momentum indicators. This suggests that while the stock may be fairly valued, it faces challenges in maintaining upward momentum in the current market environment.

Top ETFs Holding Acadia Pharmaceuticals (ACAD) Alger Weatherbie Enduring Growth ETF (NYSE:AWEG): 4.64% Weight ACAD Stock Price Activity: ACADIA Pharmaceuticals shares were up 8.60% at $26. at the time of publication on Friday, according to Benzinga Pro data.

Photo: Shutterstock

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide, is now broadly available in the United States for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. The new formulation, approved by the U.S. Food and Drug Administration (FDA) in December 2025, is bioequivalent to the original DAYBUE® oral solution, delivering the same efficacy and safety profile, while offering children and adults living with Rett syndrome new flexibility and choice regarding the dose volume and taste of their DAYBUE treatment.1

"Initial feedback from a small group of caregivers following the limited launch revealed that more than 80% of early users reported satisfaction with DAYBUE STIX, highlighting the added flexibility and portability of this new formulation,"2 said Tom Garner, Acadia’s Chief Commercial Officer. “We are hearing that the new formulation may allow for more customized care in real-world settings. Ongoing evaluation from patients and caregivers remains a priority; their perspectives are essential as we identify ways to better assist families managing this complex condition.”

The importance of flexible, patient-centered approaches was reinforced in a recent publication of expert recommendations for real-world use of trofinetide in Rett syndrome. A steering group comprised of experts based at International Rett Syndrome Foundation (IRSF)-designated centers of excellence (COEs) reached consensus recognizing trofinetide oral solution as part of the standard of care for individuals with Rett syndrome. They also aligned on key real-world considerations such as early initiation and sustained use over time. The recommendations also reflect shared perspectives on the need for individualized decision making in clinical practice to help optimize outcomes for patients, families, and caregivers.3

“The availability of DAYBUE STIX gives us an additional, flexible way to administer trofinetide, which allows us more options to address unique patient and caregiver needs,” said Arthur Beisang, M.D., Department of Pediatrics, Gillette Children's Specialty Healthcare, Saint Paul, Minn. “This patient-centered approach aligns with recently published expert consensus recommendations, which advocate for the integration of trofinetide as part of the standard of care and comprehensive Rett syndrome management. This new option provides additional customization, supporting individualized care for people with Rett syndrome.”

DAYBUE STIX is a for oral solution powder that caregivers can mix with a variety of water-based liquids such as juice, tea, lemonade, limeade, or liquid hydration so that caregivers have the ability to customize to their loved ones' taste.4 The product comes in individual packets that are easily portable.

The efficacy and safety of DAYBUE STIX is based on the results of the pivotal Phase 3 LAVENDER™ study with DAYBUE oral solution in patients with Rett syndrome.4 The approval of this new formulation was informed by the results of a bioequivalence study, which demonstrated that both original DAYBUE oral solution and the new DAYBUE STIX for oral solution powder formulation provide comparable exposure.1

Families interested in exploring this new option should speak with their healthcare provider. Acadia also offers families access to Acadia Connect®, a multi-faceted support program that offers a dedicated, experienced support team assisting with financial resources and prescription support to patients and caregivers throughout the DAYBUE treatment journey. The original oral solution formulation approved by the U.S. Food and Drug Administration in 2023 will remain available.

About Rett Syndrome

Rett syndrome is a rare, complex, neurodevelopmental disorder that may occur over four stages and occurs in approximately one of every 10,000 to 15,000 female births worldwide.5-7 In the U.S., 6,000 to 9,000 patients are affected.8 A child with Rett syndrome exhibits an early period of apparently normal development until six to 18 months, when their skills seem to slow down or stagnate. This is typically followed by a duration of regression when the child loses acquired communication skills and purposeful hand use. The child may then experience a plateau period in which they show mild recovery in cognitive interests, but body movements remain severely diminished. As they age, those living with Rett may continue to experience a stage of motor deterioration, which can last the rest of the patient’s life.6 Rett syndrome is typically caused by a genetic mutation on the MECP2 gene.9 In preclinical studies, deficiency in MeCP2 function is thought to lead to impairment in synaptic communication, and the deficits in synaptic function may be associated with Rett manifestations.9-11

Symptoms of Rett syndrome may also include development of hand stereotypies, such as hand wringing and clapping, and gait abnormalities.12 Most Rett patients typically live into adulthood and require round-the-clock care.5,13

About DAYBUE® (trofinetide) and DAYBUE® STIX (trofinetide)

Trofinetide is a synthetic analog of the N-terminal tripeptide of insulin-like growth factor-1. The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown. In animal studies, trofinetide has been shown to increase branching of dendrites and synaptic plasticity signals.14

Indication and Important Safety Information for DAYBUE® (trofinetide) and DAYBUE® STIX (trofinetide)

Indication

DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.

Important Safety Information

Warnings and Precautions Diarrhea: In a 12-week study and in long-term studies, 85% of patients treated with DAYBUE experienced diarrhea. In those treated with DAYBUE, 49% either had persistent diarrhea or recurrence after resolution despite dose interruptions, reductions, or concomitant antidiarrheal therapy. Diarrhea severity was mild or moderate in 96% of cases. In the 12-week study, antidiarrheal medication was used in 51% of patients treated with DAYBUE.
Advise patients to stop laxatives before starting DAYBUE or DAYBUE STIX. If diarrhea occurs, patients should notify their healthcare provider, consider starting antidiarrheal treatment, and monitor hydration status and increase oral fluids, if needed. Interrupt, reduce dose, or discontinue DAYBUE or DAYBUE STIX if severe diarrhea occurs or if dehydration is suspected. Vomiting: In a 12-week study, vomiting occurred in 29% of patients treated with DAYBUE and in 12% of patients who received placebo.
Patients with Rett syndrome are at risk for aspiration and aspiration pneumonia. Aspiration and aspiration pneumonia have been reported following vomiting in patients being treated with DAYBUE. Interrupt, reduce dose, or discontinue DAYBUE or DAYBUE STIX if vomiting is severe or occurs despite medical management. Weight Loss: In the 12-week study, 12% of patients treated with DAYBUE experienced weight loss of greater than 7% from baseline, compared to 4% of patients who received placebo. In long-term studies, 2.2% of patients discontinued treatment with DAYBUE due to weight loss. Monitor weight and interrupt, reduce dose, or discontinue DAYBUE or DAYBUE STIX if significant weight loss occurs. Adverse Reactions: The common adverse reactions (≥5% for DAYBUE-treated patients and at least 2% greater than in placebo) reported in the 12-week study were diarrhea (82% vs 20%), vomiting (29% vs 12%), fever (9% vs 4%), seizure (9% vs 6%), anxiety (8% vs 1%), decreased appetite (8% vs 2%), fatigue (8% vs 2%), and nasopharyngitis (5% vs 1%). Drug Interactions: Effect of DAYBUE and DAYBUE STIX on other Drugs Trofinetide, a weak inhibitor of CYP3A and an inhibitor of P-gp, can increase the plasma concentrations of CYP3A and/or P-gp substrates (e.g., loperamide), which may increase the risk of adverse reactions associated with these substrates.
Closely monitor patients when DAYBUE or DAYBUE STIX is administered concomitantly with sensitive CYP3A and/or P-gp substrates for which a minimal increase in substrate plasma concentration (i.e., drugs with a narrow therapeutic index) may lead to serious adverse reactions. Use in Specific Population: Renal Impairment DAYBUE and DAYBUE STIX are not recommended for patients with severe renal impairment. DAYBUE is available as an oral solution (200 mg/mL).

DAYBUE STIX for oral solution powder is available in 5,000 mg, 6,000 mg, and 8,000 mg packets.

Please read the full Prescribing Information also available at DAYBUEhcp.com.

About Acadia Pharmaceuticals

Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as “may,” “will,” “should,” “expects,” “anticipates,” and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) the efficacy and safety profile of DAYBUE and DAYBUE STIX and anticipated Rett syndrome symptom improvements, (ii) the flexibility in administration and allowance for customized care provided by DAYBUE STIX, (iii) the use of DAYBUE and DAYBUE STIX as the standard of care for patients with Rett syndrome and (iv) potential future use of DAYBUE and DAYBUE STIX. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties, assumptions and other factors include, but are not limited to: our ability to continue to successfully commercialize DAYBUE and DAYBUE STIX and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission on February 26, 2026, as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.

References

1

Mona D, Yamamoto A, Adegbenle Y, et al. A Phase 1, Randomized, Open-Label Study to Assess the Bioequivalence of Trofinetide as a Ready-to-Use Oral Solution and Constituted Powder for Oral Solution in Healthy Adults. Adv Ther. 2026.

2

Acadia Pharmaceuticals Inc., Data on file.

3

Prange EO, Beisang A, Pehlivan D, et al. Expert Consensus on Real-World Use of Trofinetide for Rett Syndrome Using a Modified Delphi Method. Ann Child Neurol. 2026; 4:38-51

4

Acadia Pharmaceuticals Inc. DAYBUE® [package insert]. San Diego, CA; 2025

5

Fu C, Armstrong D, Marsh E, et al. Consensus guidelines on managing Rett syndrome across the lifespan. BMJ Paediatrics Open. 2020; 4:1-14.

6

Kyle SM, Vashi N, Justice MJ. Rett syndrome: a neurological disorder with metabolic components. Open Biol. 2018; 8:170216.

7

May DM, Neul JL, Satija A, et al. Real-world clinical management of individuals with Rett syndrome: a physician survey. J of Med Econ. 26(1), 1570–1580.

8

Acadia Pharmaceuticals Inc., Data on file. RTT US Prevalence. March 2022.

9

Amir RE, Van den Veyver IB, Wan M, et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999; 23(2):185-188.

10

Fukuda T, Itoh M, Ichikawa T, et al. Delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of Mecp2-deficient mice. J Neuropathol Exp Neurol. 2005; 64(6):537-544.

11

Asaka Y, Jugloff DG, Zhang L, et al. Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome. Neurobiol Dis. 2006; 21(1):217-227.

12

Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010; 68(6):944-950.

13

Tarquinio DO, Hou W, Neul JL, et al. The changing face of survival in Rett syndrome and MECP2-related disorders. Pediatr Neurol. 2015; 53(5):402-411.

14

Acadia Pharmaceuticals Inc., Data on file. Study Report 2566-026. 2010.

More News From Acadia Pharmaceuticals Inc.

Posted by Defense World Staff on Apr 9th, 2026

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) EVP Mark Schneyer sold 2,709 shares of the firm’s stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $22.20, for a total value of $60,139.80. Following the transaction, the executive vice president directly owned 62,836 shares in the company, valued at $1,394,959.20. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

ACADIA Pharmaceuticals Stock Performance Shares of ACAD opened at $22.56 on Thursday. The firm has a market capitalization of $3.85 billion, a price-to-earnings ratio of 9.85, a price-to-earnings-growth ratio of 22.07 and a beta of 0.83. ACADIA Pharmaceuticals Inc. has a one year low of $13.40 and a one year high of $28.35. The stock’s fifty day moving average is $22.69 and its 200-day moving average is $23.79.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last released its earnings results on Thursday, February 26th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $1.48. The firm had revenue of $298.00 million for the quarter, compared to analyst estimates of $292.54 million. ACADIA Pharmaceuticals had a return on equity of 12.49% and a net margin of 36.49%.ACADIA Pharmaceuticals’s revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.86 earnings per share. Analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current fiscal year.

More ACADIA Pharmaceuticals News Here are the key news stories impacting ACADIA Pharmaceuticals this week:

Positive Sentiment: Analysts/Zacks note ACAD’s history of quarterly earnings surprises and say the company currently has the key attributes that make another beat likely — supporting upside into the next report. Will Acadia (ACAD) Beat Estimates Again in Its Next Earnings Report? (Yahoo) Will Acadia (ACAD) Beat Estimates Again in Its Next Earnings Report? (Zacks) Positive Sentiment: Acadia launched DAYBUE® STIX (trofinetide) — a dye- and preservative-free powder formulation of its Rett syndrome medicine — and said it is now broadly available in the U.S.; FDA-approved bioequivalence and easier dosing could boost uptake and sales. Acadia Announces DAYBUE STIX Now Broadly Available (BusinessWire) Positive Sentiment: Analyst coverage and institutional activity are constructive: several firms raised price targets or hold “outperform/overweight” views, and reports show large institutional stakes increasing — a supportive backdrop for the shares. Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large Moves (MarketBeat) Neutral Sentiment: Recent fundamentals: ACAD posted a sizable EPS beat in its last quarter (reported $1.60 vs. $0.12 est.) and revenue growth (~9% y/y); valuation metrics (low-teens P/E) and its 50/200-day moving averages are mixed signals for different investor horizons. ACAD Price & Profile (MarketBeat) Negative Sentiment: Insider selling: EVP Mark C. Schneyer sold 2,709 shares and director/executive James Kihara sold 1,030 shares at about $22.20 on April 7; while dollar amounts are modest relative to institutional holdings, insider sales can raise short-term caution for some investors. James Kihara Sells 1,030 Shares of ACADIA Pharmaceuticals (InsiderTrades) SEC Form 4 (Kihara) SEC Form 4 (Schneyer) Hedge Funds Weigh In On ACADIA Pharmaceuticals Hedge funds and other institutional investors have recently modified their holdings of the stock. Farther Finance Advisors LLC boosted its position in shares of ACADIA Pharmaceuticals by 67.5% in the 4th quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 386 shares during the period. Meeder Asset Management Inc. acquired a new position in shares of ACADIA Pharmaceuticals in the 4th quarter valued at $26,000. Geneos Wealth Management Inc. boosted its position in shares of ACADIA Pharmaceuticals by 113.0% in the 3rd quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 756 shares during the period. Smartleaf Asset Management LLC boosted its position in shares of ACADIA Pharmaceuticals by 107.0% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 885 shares during the period. Finally, Transamerica Financial Advisors LLC boosted its position in shares of ACADIA Pharmaceuticals by 304.5% in the 4th quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 1,005 shares during the period. Institutional investors and hedge funds own 96.71% of the company’s stock.

Analyst Ratings Changes A number of research firms recently issued reports on ACAD. JPMorgan Chase & Co. lifted their target price on ACADIA Pharmaceuticals from $31.00 to $34.00 and gave the stock an “overweight” rating in a report on Wednesday, March 4th. Citizens Jmp lifted their target price on ACADIA Pharmaceuticals from $34.00 to $35.00 and gave the stock a “market outperform” rating in a report on Thursday, February 26th. Piper Sandler set a $37.00 target price on ACADIA Pharmaceuticals in a report on Tuesday, December 16th. Oppenheimer reaffirmed a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Friday, February 6th. Finally, Wolfe Research began coverage on ACADIA Pharmaceuticals in a report on Monday, February 23rd. They set an “outperform” rating and a $33.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, ACADIA Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $31.21.

Check Out Our Latest Research Report on ACAD

About ACADIA Pharmaceuticals (Get Free Report)

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.

Featured Stories Five stocks we like better than ACADIA Pharmaceuticals

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINELarry Madden Sells 7,297 Shares of Viant Technology (NASDAQ:DSP) Stock

NEXT HEADLINE »Gershon Distenfeld Sells 5,462 Shares of AllianceBernstein Global High Income Fund (NYSE:AWF) Stock

-

Company to host conference call and webcast on Wednesday, May 6, 2026, at 4:30 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 6, 2026, at 4:30 p.m. Eastern Time.

The conference call will be available on Acadia’s website, acadia.com under the investors section and will be archived there until August 15, 2026. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.

About Acadia Pharmaceuticals

Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.

More News From Acadia Pharmaceuticals Inc.

Back to Newsroom

-

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences:

BofA Securities 2026 Health Care Conference
Fireside Chat: Tuesday, May 12, 2026 at 4:20 p.m. Pacific Time in Las Vegas, NV

2026 RBC Capital Markets Global Healthcare Conference
Fireside Chat: Tuesday, May 19, 2026 at 9:00 a.m. Eastern Time in New York, NY

Live webcasts will be accessible on the company’s website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.

About Acadia Pharmaceuticals

Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.

More News From Acadia Pharmaceuticals Inc.

Back to Newsroom

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with CSL Limited Sponsored ADR (CSLLY - Free Report) and Acadia Pharmaceuticals (ACAD - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.

The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.

Right now, CSL Limited Sponsored ADR is sporting a Zacks Rank of #2 (Buy), while Acadia Pharmaceuticals has a Zacks Rank of #3 (Hold). This means that CSLLY's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is only part of the picture for value investors.

Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.

The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.

CSLLY currently has a forward P/E ratio of 12.78, while ACAD has a forward P/E of 49.66. We also note that CSLLY has a PEG ratio of 1.45. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. ACAD currently has a PEG ratio of 23.21.

Another notable valuation metric for CSLLY is its P/B ratio of 2.11. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, ACAD has a P/B of 3.06.

Based on these metrics and many more, CSLLY holds a Value grade of B, while ACAD has a Value grade of C.

CSLLY has seen stronger estimate revision activity and sports more attractive valuation metrics than ACAD, so it seems like value investors will conclude that CSLLY is the superior option right now.

- First quarter DAYBUE® GAAP net sales of $101 million, up 20% year-over-year; successful launch of DAYBUE STIX underway

- First quarter NUPLAZID® GAAP net sales of $167 million, up 6% year-over-year on a non-GAAP adjusted basis

- Reaffirms expectation for topline results from the Phase 2 remlifanserin study in Alzheimer’s disease psychosis between August and October 2026

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2026.

“Acadia delivered a solid first quarter of 2026 with total revenues of $268 million, driven by a strong start from DAYBUE, which generated sales of $101 million,” said Catherine Owen Adams, Chief Executive Officer. “We are very encouraged by the early enthusiasm for DAYBUE STIX, which is now broadly available in the U.S., and by the initial uptake during our focused launch. NUPLAZID generated sales of $167 million, supported by strong new referrals and underlying demand, with performance strengthening as the quarter progressed. As we look ahead, we remain focused on advancing our deep, differentiated pipeline, with remlifanserin representing a key value driver as we approach expected Phase 2 topline data in Alzheimer’s disease psychosis later this year. We are reaffirming our full year guidance and remain confident in our ability to deliver long‑term value for both patients and shareholders.”

Company Updates

Full launch of DAYBUE STIX (trofinetide) in the U.S. is underway, with ~30% of STIX patients being either treatment-naive or returning after previously discontinuing the liquid formulation. Phase 2 topline results readout from the remlifanserin Alzheimer’s disease psychosis study remains on track for August to October 2026 timeframe. Accelerated enrollment in the trofinetide clinical trial in Japan, with topline results now anticipated in the September to November 2026 timeframe. Delphi expert consensus panel recently recommended DAYBUE as part of the standard of care for eligible patients with Rett syndrome.1 Financial Results

Revenues

GAAP total revenues, comprised of net product sales from NUPLAZID and DAYBUE, were $268 million for the first quarter of 2026, up 10% as compared to GAAP total revenues of $244 million in the first quarter of 2025, and up 11% as compared to non-GAAP adjusted total revenues of $242 million in the first quarter of 2025.

GAAP net product sales of NUPLAZID were $167 million for the first quarter of 2026, up 5% compared to GAAP net product sales of $160 million for the first quarter of 2025, and up 6% as compared to non-GAAP adjusted net product sales of $157 million for the first quarter of 2025.

Net product sales of DAYBUE were $101 million for the first quarter of 2026, an increase of 20% as compared to $85 million for the first quarter of 2025.

A reconciliation of NUPLAZID non‑GAAP adjusted net sales and non‑GAAP adjusted total revenues is provided in Table 1. A description of these adjustments is included under ‘Non-GAAP Financial Measures.’

Research and Development

Research and development expenses for the first quarter of 2026 were $77 million, compared to $78 million for the same period of 2025.

Selling, General and Administrative

Selling, general and administrative expenses for the first quarter of 2026 were $171 million, compared to $126 million for the same period of 2025. The increase in selling, general and administrative expenses during the first quarter was primarily driven by increased investments to support continued growth of NUPLAZID and DAYBUE.

Net Income

For the first quarter of 2026, Acadia reported net income of $4 million, or $0.02 per diluted share, compared to a net income of $19 million, or $0.11 per diluted share, for the same period in 2025.

Cash and Investments

At March 31, 2026, Acadia’s cash, cash equivalents, and investment securities totaled $851 million, compared to $820 million at December 31, 2025.

Full Year 2026 Financial Guidance (GAAP):

Acadia is reaffirming its 2026 guidance as first provided on February 25, 2026:

Total revenues in the range of $1.22 to $1.28 billion. NUPLAZID net product sales in the range of $760 to $790 million. DAYBUE net product sales in the range of $460 to $490 million. R&D expense in the range of $385 to $410 million. SG&A expense in the range of $660 to $700 million. Conference Call and Webcast Information

Acadia will host a conference call to discuss the first quarter 2026 results today, Wednesday, May 6, 2026 at 1:30 p.m. PT/4:30 p.m. ET. The conference call may be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.

About NUPLAZID® (pimavanserin)

Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors. Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis by the U.S. Food and Drug Administration in April 2016 under the trade name NUPLAZID.

About DAYBUE® (trofinetide)

Trofinetide is a synthetic version of a naturally occurring molecule known as the tripeptide glycine-proline-glutamate (GPE). The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown. Trofinetide was approved for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older by the U.S. Food and Drug Administration in March 2023 under the trade name DAYBUE or DAYBUE STIX.

About Acadia Pharmaceuticals

Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.

Non-GAAP Financial Measures

This press release contains the following financial measures that do not comply with U.S. generally accepted accounting principles (GAAP): non-GAAP adjusted net sales for NUPLAZID for the first quarter of 2025 and non-GAAP adjusted total revenues for the first quarter of 2025. In preparing these non-GAAP financial results, the Company includes adjustments made to reflect the impact of a change in estimate related to NUPLAZID IRA rebate accruals. Please refer to our press release dated February 25, 2026, for additional details. These non-GAAP financial measures complement GAAP results and are used by management to analyze financial performance and evaluate period-to-period changes. Management believes these non-GAAP financial measures are useful to investors and other users of the Company’s financial statements to facilitate period-to-period comparability. These non-GAAP financial measures are not meant to be considered as a substitute for comparable GAAP measures; should be read in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are unlikely to be comparable with non-GAAP disclosures released by other companies.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential,” “guidance,” “continue” and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) our business strategy, objectives and opportunities, including support for and innovations in our pipeline assets and business development opportunities, DAYBUE sales growth, interest in DAYBUE STIX, and potential for enhanced shareholder value; (ii) plans for, including timing, development and progress of commercialization or regulatory timelines for our products, including NUPLAZID and DAYBUE, and our product candidates; (iii) benefits to be derived from and efficacy of our products, including the potential advantages of our products; (iv) the timing and conduct of our clinical trials; and (v) our estimates regarding our future financial performance, profitability, capital requirements or expenses, including our full year 2026 financial guidance. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our dependency on the continued successful commercialization of our products and our ability to maintain or increase sales of our products; our plans to continue commercial growth; the costs of our commercialization plans and development programs, and the financial impact or revenues from any commercialization we undertake; our ability to obtain necessary regulatory approvals for our product candidates and, if and when approved, market acceptance of our products; the risks associated with clinical trials and their outcomes, including risks of unsuccessful enrollment and negative or inconsistent results; our dependence on third-party collaborators, clinical research organizations, manufacturers, suppliers and distributors; the impact of competitive products and therapies; our ability to generate or obtain the necessary capital to fund our operations; our ability to grow, equip and train our specialized sales forces; our ability to manage the growth and complexity of our organization; our ability to maintain, protect and enhance our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-K for the year ended December 31, 2025 as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.

  ACADIA PHARMACEUTICALS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

(Unaudited)

  Three Months Ended March 31,

2026

2025

Revenues

Product sales, net

$

268,062

$

244,317

Total revenues

268,062

244,317

Operating expenses

Cost of product sales (1)(2)

24,791

20,392

Research and development (2)

76,868

78,265

Selling, general and administrative (2)

171,019

126,370

Total operating expenses

272,678

225,027

(Loss) income from operations

(4,616

)

19,290

Interest income, net

8,055

7,901

Other income

542

588

Income before income taxes

3,981

27,779

Income tax expense

344

8,792

Net income

$

3,637

$

18,987

Earnings per share:

Basic

$

0.02

$

0.11

Diluted

$

0.02

$

0.11

Weighted average common shares outstanding:

Basic

170,517

166,808

Diluted

172,706

167,668

(1) Includes license fees and royalties

(2) Includes the following stock-based compensation expense

Cost of product sales

$

328

$

334

Research and development

$

4,142

$

3,433

Selling, general and administrative

$

10,228

$

7,613

  ACADIA PHARMACEUTICALS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(Unaudited)

  March 31,
2026

December 31,
2025

(unaudited)

Assets

Cash, cash equivalents and investment securities

$

851,458

$

819,686

Accounts receivable, net

135,350

121,457

Interest and other receivables

13,034

26,774

Inventory

31,574

34,670

Prepaid expenses

64,600

59,526

Total current assets

1,096,016

1,062,113

Property and equipment, net

14,652

7,511

Operating lease right-of-use assets

46,274

47,354

Intangible assets, net

106,171

108,893

Restricted cash

7,846

7,845

Long-term inventory

80,719

76,704

Deferred tax assets

249,624

249,879

Other assets

3,928

3,896

Total assets

$

1,605,230

$

1,564,195

Liabilities and stockholders’ equity

Accounts payable

$

12,246

$

10,903

Accrued liabilities

293,278

266,211

Total current liabilities

305,524

277,114

Operating lease liabilities

39,003

40,554

Other long-term liabilities

12,637

19,137

Total liabilities

357,164

336,805

Total stockholders’ equity

1,248,066

1,227,390

Total liabilities and stockholders’ equity

$

1,605,230

$

1,564,195

Table 1. ACADIA PHARMACEUTICALS INC.

NON-GAAP RECONCILIATION

(in millions)

(Unaudited)

  1Q25

1Q26

GAAP NUPLAZID Net Sales

$

159.7

$

166.9

Allocation of 2025 Amount

$

(2.3

)

$

—

Non-GAAP Adjusted NUPLAZID Net Sales

$

157.4

$

166.9

DAYBUE Net Sales

$

84.6

$

101.2

Non-GAAP Adjusted Total Revenues

$

242.0

$

268.1

References

Prange EO, Beisang A, Pehlivan D, et al. Expert Consensus on Real-World Use of Trofinetide for Rett Syndrome Using a Modified Delphi Method. Ann Child Neurol. 2026; 4:38-51. More News From Acadia Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcript